The world is running out of effective antibiotics.1
In the global race against antimicrobial resistance (AMR) and related healthcare-associated infections (HAIs), we provide diagnostic solutions that quickly and accurately identify pathogens and superbugs to enable the right isolation and treatment before it's too late. Join us in the race.
Scale of the AMR Threat
 |
 |
 |
| Deaths associated with AMR in 2019, globally2 |
Infections due to AMR per year, U.S.3 |
Extra annual healthcare costs per year, U.S.4 |
The U.S. lost progress combating AMR in 2020, in part because of the COVID-19 pandemic, with the CDC concluding that the threat of AMR infections has now gotten worse.5 During the first year of the pandemic in the US, more than 29,400 people died from AMR infections commonly associated with healthcare (a 15% increase), with nearly 40% getting the infection while they were in hospital.5
Protect Patients & Fight AMR with Fast & Accurate PCR Results in ~1 Hour*
Fast and accurate PCR with Cepheid’s GeneXpert® System greatly improves time to result, allowing healthcare professionals to quickly identify, isolate and appropriately manage colonized or infected patients, helping prevent spread.6,7
 |
Ensure the right patient is in the right bed with the right treatment for improved patient outcomes |
 |
Rapidly identify carrier status to limit transmission and guide prescribing for optimized stewardship |
 |
Standardize quality PCR diagnostic access across healthcare networks for reduced health inequalities |
Available to Download: Join the Race with our AMR Educational Pack
Outbreak Preparedness with Consolidated AMR Testing
Standardize PCR Testing for AMR & Superbugs in 3 Easy Steps
Join us in the race – MORE results, LESS spread.
That’s the PCRplus advantage. From Cepheid.
IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
For COVID-19: For use under an Emergency Use Authorization in the United States
*Turnaround times vary by test. See individual Product Inserts for specific turnaround times.
^For positive MRSA results with early assay termination. Otherwise, full runtime is 70 minutes.
#For positive Norovirus results with early assay termination. Otherwise, full runtime is 90 minutes.
MRSA: Methicillin-resistant Staphylococcus aureus. C. difficile: Clostridioides difficile. CPE: carbapenemase-producing Enterobacterales. VRE: Vancomycin-resistant Enterococcus. TB: Tuberculosis.
1. World Health Organization (WHO). July 2022 Report: Antimicrobial Resistance. Accessed April 2023 https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance?_ga=2.20730424.149613883.1682706550-1577130351.1682706550
2. Murray C, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-655.
3. CDC. : Antibiotic Resistance Threats in the United States, 2019. Accessed April 2023. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
4. Centers for Disease Control and Prevention: CDC Study Shows National Healthcare Costs from AR Infections Exceed $4.6 Billion. Accessed April 2022. https://www.cdc.gov/ncezid/what-we-do/partnership-in-action/healthcare-costs-associated-with-ar-infections.html
5. CDC. COVID-19 Reverses Progress in Fight Against Antimicrobial Resistance in U.S. Accessed May 2023. https://www.cdc.gov/media/releases/2022/s0712-Antimicrobial-Resistance.html
6. Corless C, et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. IPIP. 2020 May;3(2):100011.
7. Casari E, et al. Reducing rates of C. difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
